Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production
Jong Bok Lee(University Health Network), Aaron D. Schimmer(University of Toronto), Marina Konopleva(Albert Einstein College of Medicine), Mark D. Minden(University Health Network), Rose Hurren(Ontario Institute for Cancer Research), Zoe Alaniz(The University of Texas MD Anderson Cancer Center), Yoosu Na(University Health Network), Marcela Gronda(Ontario Institute for Cancer Research), Michael Andreeff(The University of Texas MD Anderson Cancer Center), Mingjing Xu(University Health Network), Andrea Arruda(University Health Network), Dilshad H. Khan(University of Manitoba), Xiaoming Wang(Nanjing Drum Tower Hospital), Zhang Li(University of Toronto), Neil MacLean(Ontario Institute for Cancer Research), Sara Mirali(University of Toronto), Hyeonjeong Kang(University of Toronto), Yulia Jitkova(Ontario Institute for Cancer Research)
Cited by 145
Related Papers
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
Inhibition of Mitochondrial Translation as a Therapeutic Strategy for Human Acute Myeloid Leukemia
|Cancer Cell|2011|692
Quasi-monoenergetic laser-plasma acceleration of electrons to 2 GeV
|Nature Communications|2013|641